Moleculin biotech, inc. (MBRX)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15
Revenues

0

0

0

0

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

Revenues

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

Operating expenses:
Research and development

3,206

3,197

2,785

2,099

2,932

2,928

1,332

4,231

1,237

2,286

1,061

515

683

879

497

105

15

222

38

General and administrative

1,810

1,565

1,672

1,484

1,591

1,369

1,248

1,220

1,392

1,104

1,338

800

848

533

924

618

306

293

184

Depreciation and amortization

46

51

51

49

48

42

11

7

8

4

5

5

4

4

1

1

0

0

0

Total operating expenses

5,062

4,813

4,508

3,632

4,571

4,339

2,591

5,458

2,637

3,394

2,404

1,320

1,535

1,416

1,422

724

321

515

222

Loss from operations

-5,062

-4,813

-4,508

-3,632

-4,571

-4,339

-2,591

-5,458

-2,637

-3,394

-2,404

-1,320

-1,535

-1,416

-1,422

-724

-321

-515

-222

Other income:
Gain (loss) from change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-470

-3,342

-

-

-

-

-

-

-

Gain from change in fair value of warrant liability

-3,845

-1,002

-124

-2,407

-529

-1,572

-573

-331

-709

-

-

-

-1,059

0

0

0

0

-

-

Gain from settlement of liability

-

-

-

-

-

-

-

-

-

0

0

0

149

0

0

0

0

-

-

Gain from expiration of warrants

-

-

-

-

-

-

-

-

-

-

0

1,238

-

-

0

0

-

-

-

Other income, net

5

10

5

0

0

-

-21

-1

-

-

9

0

-

-

-

-

-

-

-

Other income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Other expense

-

-

-

-

-

-

-

-

-

-

-

-

1

-

-

0

0

-

-

Interest income, net

3

3

5

4

1

-1

1

3

1

2

-1

0

-1

-

-

-

-

-

-

Net loss before taxes

-

-

-4,374

-

-

-

-2,038

-

-

-

-

-

-

-

-

-

-

-

-

Income tax benefit

-

-

-200

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense, net

-

-

-

-

-

-

-

-

-

-

-

-

-

7

10

15

11

8

1

Net loss

-1,209

-3,798

-4,145

-1,221

-4,041

-2,786

-2,038

-5,125

-1,927

-3,186

-2,866

-3,424

-329

-1,423

-1,432

-739

-332

-524

-224

Net loss per common share - basic and diluted (in dollars per share)

-0.02

-0.06

-0.09

-0.03

-0.14

-0.10

-0.08

-0.20

-0.08

-0.18

-0.14

-0.19

-0.02

-0.15

-0.12

-0.08

-0.05

-0.08

-0.05

Weighted average common shares outstanding, basic and diluted (in shares)

49,930

45,962

45,464

42,393

29,064

27,534

26,861

25,888

23,331

21,288

20,534

17,863

14,590

12,137

11,579

8,875

6,717

7,063

4,320

Comprehensive loss:
Net loss

-1,209

-3,798

-4,145

-1,221

-4,041

-2,786

-2,038

-5,125

-1,927

-

-2,866

-3,424

-

-

-

-

-

-

-

Other comprehensive income (loss):
Foreign currency translation

-33

12

-3

-2

-11

14

15

6

0

-

0

0

-

-

-

-

-

-

-

Comprehensive loss

-1,242

-3,786

-4,148

-1,223

-4,052

-2,772

-2,023

-5,119

-1,927

-

-2,866

-3,424

-

-

-

-

-

-

-